3 unchanged sentences
In January 2019, our Board of Directors established the current $10 million repurchase program to replace the prior authorizations for repurchases of our outstanding common stock.
−Removed: The following table summarizes the activity, by month, during the three months ended March 31, 2023:
+Added: The following table summarizes the activity, by month, during the three months ended June 30, 2023:
Period Total Number of
6 unchanged sentences
Purchased Under
−Removed: January 18,122 $ 2.60 $ 3,706,634
−Removed: February 10,663 2.63 3,678,628
−Removed: March 58,044 1.94 3,565,836
−Removed: 10.1* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between A.J.
−Removed: Kazimi and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.11 of the Company’s Current Report on Form 8-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
−Removed: 10.2* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Jim Herman and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.12 of the Company’s Current Report on Form 8-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
−Removed: 10.3* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Todd Anthony and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.13 of the Company’s Current Report on Form 8-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
−Removed: 10.4* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between Chris Bitterman and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.14 of the Company’s Current Report on Form 8-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
−Removed: 10.5* Employment Agreement dated March 9, 2023, effective as of January 1, 2023, by and between John M.
−Removed: Hamm and Cumberland Pharmaceuticals Inc.
−Removed: (incorporated by reference to Exhibit 10.15 of the Company’s Current Report on Form 8-K, File No.
−Removed: 001-33637, filed with the Securities and Exchange Commission on March 15, 2023).
+Added: April 15,270 $ 1.96 $ 3,535,851
+Added: May 32,427 1.73 3,479,730
+Added: June 51,360 1.66 3,394,220
+Added: 10.1 Amendment Number 3 to the Amended and Restated 2007 Long-Term Incentive Compensation Plan, incorporated herein by reference to Appendix A of the Company’s Schedule 14A (File No.:
+Added: 001-33637) as filed with the SEC on March 15, 2023 and approved by the Company's shareholders on April 25, 2023.
31.1* Certification of Chief Executive Officer Pursuant to Rule 13-14(a) of the Securities Exchange Act of 1934 as Adopted Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
13 unchanged sentences
Cumberland Pharmaceuticals Inc.
−Removed: May 12, 2023 By:
+Added: August 11, 2023 By:
/s/ John Hamm
1 unchanged sentence
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.